

BEST AVAILABLE COPY

IN THE U.S. PATENT AND TRADEMARK OFFICE

In re Application of

Lars LANNFELT

Application No. 09/899,815

Filed July 9, 2001

Conf. 9645

Group 1649

Examiner O. Chernyshev

PREVENTION AND TREATMENT OF
ALZHEIMER'S DISEASE

DECLARATION UNDER RULE 132

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Dr. Lars LANNFELT, hereby declare as follows:

I am the inventor of the present application. I have read the application and I am familiar with the prosecution of the present application.

It is my understanding that claims 27, 32-33, 44-45, and 48-50 are rejected under 35 USC §112, second paragraph, for allegedly being indefinite. In imposing the rejection, the Patent Office states that the recitation "wherein said antibody binds to said A β -Arc peptide" should be recited in the pending claims.

However, it is respectfully submitted that this does not accurately reflect the nature of the present invention. The present disclosure teaches that the claimed antibodies will bind with A β -Arc and A β wild-type peptides in a protofibril state. This is supported in the present specification at page 4, lines 8-9 and page 8, lines 10-15.

27

MAR-03-2006 13:20 FROM: YOUNG & THOMPSON

703 685 2573

TD:018568939

P.3/4


Application No. 09/899,815
Docket No. 1510-1030

In addition, I present the following experimental results which provide further evidence that the claimed antibodies bind to wild-type A β peptide and A β -Arc peptide in their protofibril conformation.

By following the teachings of the present disclosure, a class of protofibril-specific monoclonal antibodies were developed by immunizing mice with A β -Arc peptide in its protofibril conformation.

In Exp. 1 shown below, a sandwich ELISA is used to demonstrate that a protofibril specific antibody, produced according to the present disclosure, binds to both wild-type A β peptide and A β -Arc peptide in their protofibril conformation.

Exp. 1.



Exp. 1 Binding properties of a protofibril specific monoclonal antibody determined by a sandwich ELISA

Equal amounts of a protofibril-specific monoclonal antibody were bound to each well in a micro-titer plate. A β wild-type protofibrils and A β -Arc protofibrils were subsequently added to different wells in increasing

2006 03/07 10:40 FAX
2006 03/07 10:02 FAX 018588939

003
004/004

MAR-03-2006 13:20 FROM: YOUNG & THOMPSON

703 885 0573

TO: 018588939

P.4/4

Application No. 09/899,815
Docket No. 1510-1030

concentrations, and allowed to bind. Binding was subsequently measured by a second antibody labeled with ALP at 405 nm. The protofibril-specific antibody bound to both Arctic and wild-type protofibrils.

Thus, in view of the above, applicant believes that the present specification and experimental results show that the claimed antibodies bind to wild-type A β peptide and A β -Arc peptide in their protofibril conformation.

The undersigned declare further that all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Uppsala March 7, 2006
Date

Lars Lannfelt
Dr. Lars Lannfelt